Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
A promising molecular diagnostic tool for detecting primary bladder cancer in patients who notice blood in their urine may speed up diagnosis and reduce the need for potentially unnecessary ...
A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer. A urine-based test may decrease the number of invasive cystoscopies in ...
A streamlined urine DNA test more accurately detects primary bladder cancer, reducing the need for more invasive cystoscopy, reports The Journal of Molecular Diagnostics Lead investigator Sungwhan An, ...